Loading
A phase 2 trial of Pembrolizumab in cervical cancer, run by Precigen, Inc, now recruiting.
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer is a phase 2 interventional study registered as NCT06157151 by Precigen, Inc, with 24 participants planned, started 2025-11-11 and due to reach its primary completion in 2026-11-11. Interventions recorded: PRGN-2009 plus Pembrolizumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Precigen and the tag pipeline.
Shares Recurrent or metastatic cervical cancer, Cervical cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Recurrent or metastatic cervical cancer, Cervical cancer and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Recurrent or metastatic cervical cancer, Cervical cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/